Isarna Therapeutics Unveils New Selective TGF-beta Antagonist Program
News Jan 09, 2015
Isarna Therapeutics has announced that it has submitted a Clinical Trial Authorization (CTA) application with the German Regulatory Authority to begin human studies on its lead program ISTH0036, a selective TGF-ß2 antisense oligonucleotide.
TGF-ß2 is considered a prime disease driver in major ophthalmic diseases such as glaucoma, secondary cataract, and proliferative vitreoretinopathy.
“Glaucoma is the leading cause of irreversible blindness worldwide. By targeting TGF-ß2 we believe that ISTH0036 represents an important innovative and so far unexplored new approach to stopping and potentially modifying the course of the disease in its advanced stages and, therefore, it addresses a high unmet medical need,” stated Dr. Philippe Calais, CEO of Isarna. “We expect to begin studies in the first half of 2015 and are seeking funding to advance this as well as our lead TGF-ß isoform specific programs in fibrosis and oncology through the proof-of-concept stage.”
Dr. Calais continued, “Isarna made significant progress during the course of 2014, as it was only a year ago that we announced our agreement with Santaris providing us with exclusive access to their LNA chemistry technology, and today we announce our first CTA filing for a major disease in ophthalmology.”
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018